Spruce Biosciences Reports Q3 GAAP EPS Miss and Increased Cash Position
Spruce Biosciences (SPRB) reported third-quarter GAAP earnings per share of -$8.51, missing analyst expectations by $2.83. Despite the earnings miss, the company saw a significant increase in its liquidity position. As of September 30, 2026, Spruce Biosciences held $87.7 million in cash and cash equivalents, up from $48.9 million at the end of 2025. Management stated that current cash reserves are expected to be sufficient to fund planned operations and debt obligations through the second half of 2027.